Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Neoadjuvant for Resectable NSCLC
NCT07035392Phase 2Not yet recruiting
- Sponsor
- Zhangzhou Municipal Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Zhangzhou Municipal Hospital. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07035392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035392.